Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
1.940
-0.020 (-1.02%)
At close: Jan 21, 2025, 4:00 PM
1.920
-0.020 (-1.03%)
After-hours: Jan 21, 2025, 7:59 PM EST
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $72.10K. In the year 2023, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
88.32
Revenue / Employee
$24,034
Employees
3
Market Cap
8.70M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
SILO News
- 19 days ago - Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - GlobeNewsWire
- 4 weeks ago - Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia - GlobeNewsWire
- 7 weeks ago - Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management - GlobeNewsWire
- 2 months ago - Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders - GlobeNewsWire
- 2 months ago - Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - GlobeNewsWire
- 4 months ago - Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD - GlobeNewsWire
- 5 months ago - Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic - GlobeNewsWire
- 5 months ago - Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide - GlobeNewsWire